NCT06753565 L-carnitine Supplementation in Rheumatoid Arthritis Patients
| NCT ID | NCT06753565 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | German University in Cairo |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-12-31 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2024-12-31 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.
Eligibility Criteria
Inclusion Criteria: * age between 18-60 years old * diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months * enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study * active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2) * patient or legal representative should sign informed consent Exclusion Criteria: * pregnant or lactating female * patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST) * Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl) * Patients with any active infection or concurrent malignancy * patients with uncontrolled medical conditions or other rheumatic diseases * patients currently taking drugs that could interact with carnitine like: warfarin
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06753565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06753565 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06753565 currently recruiting?
Yes, NCT06753565 is actively recruiting participants. Contact the research team at mariam.ehab-azmy@guc.edu.eg for enrollment information.
Where is the NCT06753565 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06753565 clinical trial?
NCT06753565 is sponsored by German University in Cairo. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.